Indegene (INDGN) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue reached INR 7,608 million, up 12.5% year-over-year and 0.7% sequentially, with strong performance in enterprise segments and new initiatives like Tectonic gaining traction.

• EBITDA stood at INR 1,536 million, with a stable margin of 20.2%; PAT was INR 1,164 million, up 32.7% year-over-year.

• Strategic priorities include expanding AI-enabled solutions, strengthening sales and consulting leadership, and pursuing M&A opportunities.

• Financial results were prepared in accordance with Ind AS 34 and SEBI regulations, reviewed by the Audit Committee and Board, with an unmodified auditor's opinion.

• Industry outlook remains stable with continued pressure on drug pricing, driving demand for digital transformation and AI adoption in pharma operations.

Financial highlights

• Revenue from operations reached INR 7,608 million, up 12.5% year-over-year and 0.7% quarter-on-quarter.

• EBITDA margin was stable at 20.2%; PAT margin at 15.3%, down 30 bps sequentially.

• Profit after tax was INR 1,164 million, up 32.7% YoY; basic EPS (consolidated) for Q1 FY26 was ₹4.86.

• Cash and cash equivalents reached INR 17,280 million.

• Standalone revenue for Q1 FY26 was ₹2,556 million, with net profit at ₹451 million.

Outlook and guidance

• Management expects continued growth momentum, supported by a strong pipeline, large transformative deals, and ongoing investments in new business lines and M&A.

• AI and digital transformation are expected to drive differentiation and market share gains.

• No explicit forward-looking guidance provided, but segment and revenue growth trends indicate continued momentum.